CUX1 and neoplasm: While patients with recurrence and high CUX1 expression showed a median overall survival (mOS) of 71 months, the survival of patients with CUX1 low-expressing tumours did not reach the median (p = 0.27), indicating extended survival beyond the time of censoring due to end of follow-up.